Does Rallies show 13F holders for MAZE?

Yes. Rallies tracks hedge fund and 13F ownership data for MAZE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MAZE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MAZE. It does not provide personalized investment advice.

MAZE (Maze Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Maze Therapeutics, Inc. Common Stock (MAZE) is a publicly traded Healthcare sector company. As of May 21, 2026, MAZE trades at $25.03 with a market cap of $1.36B and a P/E ratio of -9.98. MAZE moved +2.37% today. Year to date, MAZE is -35.21%; over the trailing twelve months it is +147.58%. Its 52-week range spans $6.71 to $53.65. Analyst consensus is strong buy with an average price target of $63.50. Rallies surfaces MAZE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MAZE stock?

Hedge funds tracked by Rallies that own MAZE include Matrix Capital, Farallon Capital, and Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Maze Therapeutics, Inc. Common Stock.

MAZE Key Metrics

Key financial metrics for MAZE
Metric	Value
Price	$25.03
Market Cap	$1.36B
P/E Ratio	-9.98
EPS	$-2.48
Dividend Yield	0.00%
52-Week High	$53.65
52-Week Low	$6.71
Volume	0
Avg Volume	0
Revenue (TTM)	$20.00M
Net Income	$-122.54M
Gross Margin	0.00%

Top Hedge Funds Holding MAZE

Matrix Capital holds 480.00K shares of MAZE, changed -70.97% as of Dec 31, 2025.
Farallon Capital holds 373.00K shares of MAZE, changed +0.00% as of Mar 31, 2026.
Mangrove Partners holds 6.75K shares of MAZE, changed +0.00% as of Mar 31, 2026.

Latest MAZE News

Maze Therapeutics Secures $150M Financing to Fund Pipeline Through 2029 — Apr 22, 2026
Maze’s MZE829 Cuts Proteinuria 35.6%, Moves to Pivotal Trials as Stock Falls 18.3% — Mar 25, 2026
Maze Therapeutics Eyes 30% UACR Reduction in MZE829 and >40-Fold MZE782 Biomarker Rise — Feb 14, 2026

Recent MAZE Insider Trades

Coloma Jason V sold 1.82K (~$47.37K) on May 15, 2026.
Coloma Jason V sold 116 (~$3.02K) on May 15, 2026.
Bernstein Harold sold 15.00K (~$393.35K) on May 14, 2026.

MAZE Analyst Consensus

12 analysts cover MAZE: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.50.

Common questions about MAZE

Who owns MAZE stock?: Hedge funds tracked by Rallies that own MAZE include Matrix Capital, Farallon Capital, and Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Maze Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for MAZE?: Yes. Rallies tracks hedge fund and 13F ownership data for MAZE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MAZE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MAZE. It does not provide personalized investment advice.